Evidence map›Paper›PMID 31113876›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

Interrogating dense ligand chemical space with a forward-synthetic library.

Florent Chevillard, Silvia Stotani, Anna Karawajczyk, Stanimira Hristeva, Els Pardon, Jan Steyaert, Dimitrios Tzalis, Peter Kolb

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. SAR by Space: Enriching Hit Sets from the Chemical Space.Molecules (Basel, Switzerland) · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Florent ChevillardDepartment of Pharmaceutical Chemistry, Philipps-University Marburg, 35032 Marburg, Germany.
Silvia StotaniTaros Chemicals GmbH & Co. KG, 44227 Dortmund, Germany.
Anna KarawajczykTaros Chemicals GmbH & Co. KG, 44227 Dortmund, Germany.
Stanimira HristevaTaros Chemicals GmbH & Co. KG, 44227 Dortmund, Germany.
Els PardonVlaams Instituut voor Biotechnologie-Vrije Universiteit Brussel Center for Structural Biology, Vlaams Instituut voor Biotechnologie, 1050 Brussels, Belgium.ORCID 0000-0002-2466-0172
Jan SteyaertVlaams Instituut voor Biotechnologie-Vrije Universiteit Brussel Center for Structural Biology, Vlaams Instituut voor Biotechnologie, 1050 Brussels, Belgium.
Dimitrios TzalisTaros Chemicals GmbH & Co. KG, 44227 Dortmund, Germany; peter.kolb@uni-marburg.de dtzalis@taros.de.
Peter KolbDepartment of Pharmaceutical Chemistry, Philipps-University Marburg, 35032 Marburg, Germany; peter.kolb@uni-marburg.de dtzalis@taros.de.ORCID 0000-0003-4089-614X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Forward-synthetic databases are an efficient way to enumerate chemical space. We explored here whether these databases are good sources of novel protein ligands and how many molecules are obtainable and in which time frame. Based on docking calculations, series of molecules were selected to gain insights into the ligand structure-activity relationship. To evaluate the novelty of compounds in a challenging way, we chose the β

Indexed as

de novo designdockingforward synthetic librarieshighly designed librariesparallel synthesis

Identifiers

PMID31113876
PMCPMC6561289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.